By Professor David Goldstein

Journal articles

Tempero M; O'Reilly E; Van Cutsem E; Berlin J; Philip P; Goldstein D; Tabernero J; Borad M; Bachet J; Parner V; Tebbutt N; Chua Y; Corrie P; Harris M; Taieb J; Burge M; Kunzmann V; Zhang G; McGovern D; Marks H; Biankin A; Reni M, 2021, 'LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival', Annals of Oncology, 32, pp. S226 - S226, http://dx.doi.org/10.1016/j.annonc.2021.06.009

Kokkinos J; Ignacio RM; Haghighi K; Kopecky C; Sharbeen G; Gonzales-Aloy E; Youkhana J; Butler L; Goldstein D; McCarroll J; Phillips P, 2021, 'Patient-derived pancreatic tumours in a dish: implications for real-time precision medicine', HPB, 23, pp. S235 - S235, http://dx.doi.org/10.1016/j.hpb.2020.11.590

Maharaj AD; Evans SM; Zalcberg JR; Ioannou LJ; Graco M; Croagh D; Pilgrim CHC; Dodson T; Goldstein D; Philip J; Kench JG; Merrett ND; Neale RE; White K; Evans P; Leong T; Green SE, 2020, 'Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework', PLoS ONE, 15, http://dx.doi.org/10.1371/journal.pone.0243312

Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'Targeting hgf/c-met axis in pancreatic cancer', International Journal of Molecular Sciences, 21, pp. 1 - 18, http://dx.doi.org/10.3390/ijms21239170

McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW, 2020, 'Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer', Journal of Hepatology, 73, pp. 1109 - 1117, http://dx.doi.org/10.1016/j.jhep.2020.05.014

Xu Z; Pothula S; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis', British Journal of Cancer, 123, pp. 1466, http://dx.doi.org/10.1038/s41416-020-1004-6

McGahan W; Waterhouse MA; O'Connell DL; Merrett ND; Goldstein D; Wyld D; Burmeister EA; Jordan SJ; Neale RE, 2020, 'Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis', Pancreatology, 20, pp. 1458 - 1464, http://dx.doi.org/10.1016/j.pan.2020.07.405

Pang TCY; Xu Z; Mekapogu AR; Pothula S; Becker TM; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'An orthotopic resectional mouse model of pancreatic cancer', Journal of Visualized Experiments, 2020, pp. 1 - 13, http://dx.doi.org/10.3791/61726

Lees JG; White D; Keating BA; Barkl-Luke ME; Makker PGS; Goldstein D; Moalem-Taylor G, 2020, 'Oxaliplatin-induced haematological toxicity and splenomegaly in mice', PLoS ONE, 15, http://dx.doi.org/10.1371/journal.pone.0238164

Timmins HC; Li T; Kiernan MC; Baron-Hay S; Marx G; Boyle F; Goldstein D; Park SB, 2020, 'Taxane-induced peripheral neuropathy: differences in patient report and objective assessment', Supportive Care in Cancer, 28, pp. 4459 - 4466, http://dx.doi.org/10.1007/s00520-020-05299-y

Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB, 2020, 'Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials', Hematological Oncology, 38, pp. 229 - 243, http://dx.doi.org/10.1002/hon.2706

Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Boyle F; Goldstein D; Park SB, 2020, 'Electrophysiological and phenotypic profiles of taxane-induced neuropathy', Clinical Neurophysiology, 131, pp. 1979 - 1985, http://dx.doi.org/10.1016/j.clinph.2020.02.028

Tran B; Vajdic CM; Webber K; Laaksonen MA; Stavrou EP; Tiller K; Suchy S; Bosco AM; Harris MF; Lloyd AR; Goldstein D, 2020, 'Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study', Cancer Epidemiology, 67, http://dx.doi.org/10.1016/j.canep.2020.101773

Makker PGS; White D; Lees JG; Parmar J; Goldstein D; Park SB; Howells J; Moalem-Taylor G, 2020, 'Acute changes in nerve excitability following oxaliplatin treatment in mice', Journal of Neurophysiology, 124, pp. 232 - 244, http://dx.doi.org/10.1152/jn.00260.2020

Goldstein D; Von Hoff DD; Chiorean EG; Reni M; Tabernero J; Ramanathan RK; Botteman M; Aly A; Margunato-Debay S; Lu B; Louis CU; McGovern D; Lee CK, 2020, 'Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer', Pancreas, 49, pp. 744 - 750, http://dx.doi.org/10.1097/MPA.0000000000001563

Barbour AP; Samra JS; Haghighi KS; Donoghoe MW; Burge M; Harris MT; Chua YJ; Mitchell J; O’Rourke N; Chan H; Gebski VJ; Gananadha S; Croagh DG; Kench JG; Goldstein D; Barbour A; Goldstein D; Samra JS; Harris M; Chua YJ; Yip S; Simes J; Hicks R; Coates A; Gurney H; Do V; Marschner I; Mitchell J; Donoghoe M; Goldstone S; Yip S; Chua YJ; Pavlakis N; Goldstein D; Aghmesheh M; Joubert W; Grimes D; Harris M; Burge M; Bagia S; Jaber M; Gananadha S; Bryant R; Nathanson L; Cavallucci D; Barbour A; Fawcett J; O’Rourke T; Croagh D; Jones R, 2020, 'The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer', Annals of Surgical Oncology, 27, pp. 2506 - 2515, http://dx.doi.org/10.1245/s10434-020-08205-2

Chiang JCB; Zahari I; Markoulli M; Krishnan AV; Park SB; Semmler A; Goldstein D; Edwards K, 2020, 'The impact of anticancer drugs on the ocular surface', Ocular Surface, 18, pp. 403 - 417, http://dx.doi.org/10.1016/j.jtos.2020.03.008

Lim BT; Butow P; Sze ML; Girgis A; Jefford M; Goldstein D; Costa D, 2020, 'Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups', Asia-Pacific Journal of Clinical Oncology, 16, pp. 115 - 122, http://dx.doi.org/10.1111/ajco.13290

Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; Van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG, 2020, 'Quality of surgery and outcome in localized gastrointestinal stromal tumors treated within an international intergroup randomized clinical trial of adjuvant imatinib', JAMA Surgery, 155, http://dx.doi.org/10.1001/jamasurg.2020.0397

Reni M; Riess H; O'Reilly EM; Reeves JA; Chiorean E; George TJ; Scheithauer W; Pascal A; Lerch M; Brenner WS; Ko Y-J; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Biankin A; Tempero MA, 2020, 'Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.', Journal of Clinical Oncology, 38, pp. 4618 - 4618, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4618

Battaglini E; Goldstein D; Park S, 2020, 'Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.', Journal of Clinical Oncology, 38, pp. e24080 - e24080, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e24080

Butow P; Davies G; Napier C; Thomas DM; Bartley N; Goldstein D; Ballinger ML; Juraskova I; Schlub TE; Tucker K; Meiser B; Young M-A, 2020, 'Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.', Journal of Clinical Oncology, 38, pp. 1541 - 1541, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1541

Butow P; Butow P; Davies G; Napier CE; Schlub T; Best MC; Bartley N; Juraskova I; Meiser B; Ballinger ML; Biesecker B; Goldstein D; Thomas DM, 2020, 'Assessment of the Value of Tumor Variation Profiling Perceived by Patients with Cancer', JAMA Network Open, 3, pp. e204721, http://dx.doi.org/10.1001/jamanetworkopen.2020.4721

Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis', British Journal of Cancer, 122, pp. 1486 - 1495, http://dx.doi.org/10.1038/s41416-020-0782-1

Oar A; Lee M; Le H; Hruby G; Dalfsen R; Pryor D; Lee D; Chu J; Holloway L; Briggs A; Barbour A; Chander S; Ng SP; Samra J; Shakeshaft J; Goldstein D; Nguyen N; Goodman KA; Chang DT; Kneebone A, 2020, 'Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)', Practical Radiation Oncology, 10, pp. e136 - e146, http://dx.doi.org/10.1016/j.prro.2019.07.018

Kokkinos J; Ignacio RMC; Sharbeen G; Boyer C; Gonzales-Aloy E; Goldstein D; McCarroll JA; Phillips PA, 2020, 'Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs', Biomaterials, 240, http://dx.doi.org/10.1016/j.biomaterials.2019.119742

Sahai V; Tabernero J; Van Cutsem E; Reni M; Tempero MA; O'Reilly EM; Berlin J; Riess H; Goldstein D; Li M; Lu B; Ferrara S; Philip PA, 2020, 'Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns.', Journal of Clinical Oncology, 38, pp. 704 - 704, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.704

Best MC; Butow P; Jacobs C; Savard J; Biesecker B; Ballinger ML; Bartley N; Davies G; Napier CE; Smit AK; Thomas DM; Newson AJ, 2020, 'Who should access germline genome sequencing? A mixed methods study of patient views', Clinical Genetics, 97, pp. 329 - 337, http://dx.doi.org/10.1111/cge.13664

Tjokrowidjaja A; Goldstein D; Hudson HM; Lord SJ; Gebski V; Clarke S; de Souza P; Motzer RJ; Lee CK, 2020, 'The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy', Acta Oncologica, 59, pp. 20 - 27, http://dx.doi.org/10.1080/0284186X.2019.1656342

Timmins HC; Li T; Kiernan MC; Horvath LG; Goldstein D; Park SB, 2020, 'Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients', Journal of Pain, 21, pp. 44 - 58, http://dx.doi.org/10.1016/j.jpain.2019.06.011

Wang X; Yeo RX; Hogg PJ; Goldstein D; Crowe P; Dilda PJ; Yang JL, 2020, 'The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas', Oncotarget, 11, pp. 46 - 61, http://dx.doi.org/10.18632/oncotarget.27416

Perera C; Xu Z; Mekapogu AR; Hosen SMZ; Pothula S; Greenfield J; Chari S; Goldstein D; Pirola R; Wilson J; Apte MV, 2020, '1133 PANCREATIC STELLATE CELL AND CANCER CELL DERIVED EXOSOMES IMPAIR BETA CELL FUNCTION: IMPLICATIONS FOR PANCREATIC CANCER RELATED DIABETES.', Gastroenterology, 158, pp. S - 221, http://dx.doi.org/10.1016/s0016-5085(20)31245-2

Li T; Timmins HC; McCrary JM; Trinh T; Horvath LG; Friedlander ML; Kiernan MC; Goldstein D; Park SB, 2020, '5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients', Clinical Neurophysiology, 131, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2019.11.038

Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Marx G; Boyle F; Goldstein D; Park SB, 2020, '8. Electrophysiological and phenotypic profiles of taxane-induced neuropathy', Clinical Neurophysiology, 131, pp. e4 - e4, http://dx.doi.org/10.1016/j.clinph.2019.11.041

Kokkinos J; Sharbeen G; Haghighi K; Ignacio RM; Kopecky C; Gonzales-Aloy E; Youkhana J; Pandzic E; Boyer C; Davis T; Butler L; Goldstein D; McCarroll J; Phillips P, 2020, 'Bringing the pancreas patient back to the bench: Ex vivo culture of intact human patient derived pancreatic tumour tissue', , http://dx.doi.org/10.1101/2020.07.30.223925

Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D, 2019, 'Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade', Supportive Care in Cancer, 27, pp. 4771 - 4777, http://dx.doi.org/10.1007/s00520-019-04781-6

McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB, 2019, 'Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy', Journal of Pain and Symptom Management, 58, pp. 1023 - 1032, http://dx.doi.org/10.1016/j.jpainsymman.2019.07.021

Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B, 2019, 'Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer', Oncologist, 24, pp. e1102 - e1107, http://dx.doi.org/10.1634/theoncologist.2018-0613

Tang M; Chen J; Goldstein D; Links M; Lord S; Marschner I; Simes RJ; Lee CK, 2019, 'Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer', Pancreas, 48, pp. 1274 - 1284, http://dx.doi.org/10.1097/MPA.0000000000001429

Li T; Timmins H; King T; Kiernan M; Goldstein D; Park S, 2019, 'Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19, pp. E346 - E346, http://dx.doi.org/10.1016/j.clml.2019.09.571

McCrary JM; Goldstein D; Sandler CX; Barry BK; Marthick M; Timmins HC; Li T; Horvath L; Grimison P; Park SB, 2019, 'Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 27, pp. 3849 - 3857, http://dx.doi.org/10.1007/s00520-019-04680-w

McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; Andre T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater JA; Valle JW, 2019, 'Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial', ANNALS OF ONCOLOGY, 30, pp. 274 - 274, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295502144&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P, 2019, 'Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer', Annals of Oncology, 30, pp. 1472 - 1478, http://dx.doi.org/10.1093/annonc/mdz200

Maharaj AD; Holland JF; Scarborough RO; Evans SM; Ioannou LJ; Brown W; Croagh DG; Pilgrim CHC; Kench JG; Lipton LR; Leong T; McNeil JJ; Nikfarjam M; Aly A; Burton PR; Cashin PA; Chu J; Duong CP; Evans P; Goldstein D; Haydon A; Hii MW; Knowles BPF; Merrett ND; Michael M; Neale RE; Philip J; Porter IWT; Smith M; Spillane J; Tagkalidis PP; Zalcberg JR, 2019, 'The Upper Gastrointestinal Cancer Registry (UGICR): A clinical quality registry to monitor and improve care in upper gastrointestinal cancers', BMJ Open, 9, pp. e031434, http://dx.doi.org/10.1136/bmjopen-2019-031434

McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB, 2019, 'Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test', Journal of Cancer Survivorship, 13, pp. 495 - 502, http://dx.doi.org/10.1007/s11764-019-00769-7

Best MC; Bartley N; Jacobs C; Juraskova I; Goldstein D; Newson AJ; Savard J; Meiser B; Ballinger M; Napier C; Thomas D; Biesecker B; Butow P; Tucker K; Schlub T; Vines R; Vines K; Kirk J; Young MA, 2019, 'Patient perspectives on molecular tumor profiling: "why wouldn't you?"', BMC Cancer, 19, pp. 753, http://dx.doi.org/10.1186/s12885-019-5920-x

Reni M; Riess H; O'Reilly E; Santoro A; Park J; Bekaii-Saab T; Tempero M; Shan Y; Macarulla T; Van Cutsem E; Noel M; Berlin J; Biankin A; Dhani N; Frassineti G; Goldstein D; Romano A; Bruchec YL; Philip P, 2019, 'An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes', Annals of oncology : official journal of the European Society for Medical Oncology, 30, pp. iv126, http://dx.doi.org/10.1093/annonc/mdz154

Reni M; Winter J; Tortora G; Pelzer U; Riess H; Chang H; O'Reilly E; Oh D; Diaz IA; Milella M; Bendell J; Garlipp B; Tempero M; Macarulla T; Van Cutsem E; Berlin J; Goldstein D; Lu B; Jeanes J; Philip P, 2019, 'Analysis of patient screening in the phase III, international, randomized, open-label APACT trial', Annals of oncology : official journal of the European Society for Medical Oncology, 30, pp. iv110, http://dx.doi.org/10.1093/annonc/mdz156

Tempero MA; Reni M; Riess H; Pelzer U; O'Reilly EM; Winter JM; Oh D-Y; Li C-P; Tortora G; Chang H-M; Lopez CD; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Ferrara S; Li M; Lu BD; Biankin A, 2019, 'APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.', Journal of Clinical Oncology, 37, pp. 4000 - 4000, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4000

Thavaneswaran S; Napier C; Goldstein D; Meiser B; Butow P; Thomas DM; Ballinger ML; Best M, 2019, 'Medical oncologists’ experience with returning molecular tumor profiling to patients.', Journal of Clinical Oncology, 37, pp. 10521 - 10521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10521

Back to profile page